Connect
← Return to Price of Xtandi (in U.S.)?
Discussion
Prostate Cancer | Last Active: 2 hours ago | Replies (14)
Comment receiving replies
I think the baseline U.S. patent for Enzalutamide/Xtandi (the oldest -lutamide) expires in 2027. It will be interesting to see if oncologists who currently nudge patients towards Abiraterone suddenly change their tune when there's a cheap generic -lutamide available and U.S. private insurers are no longer objecting to the extra cost. 🤷
Replies to "I think the baseline U.S. patent for Enzalutamide/Xtandi (the oldest -lutamide) expires in 2027. It will..."
Connect
The thing is, using abiraterone first can give you an extended amount of time of non-progression of your cancer. This Lancet article discusses why using abiraterone first makes sense.
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30688-6/abstract?mc
cid=c2dca8aa74&mc_eid=99575fc699
These drugs last only so long before your body starts to have a rise in PSA. I was able to stay on abiraterone For 2 1/2 years before moving to Darolutamide. I would hope Darolutamide will work for three or four more years. I know it’s very unlikely that abiraterone would last 5 1/2 to 6 1/2 years before my PSA would start rising. I think using both has given me more time.